Literature DB >> 32661295

Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?

Marie Robin1, Pierre Fenaux2.   

Abstract

Indications of allogeneic hematopoietic stem cell transplantation (HSCT) remain controversial in patients with lower risk myelodysplastic syndrome. We review prognostic factors in lower risk MDS, delineating patients with relatively poor risk who may potentially benefit from HSCT during the disease course. Results of HSCT in those patients, and main efforts to decrease non-relapse mortality (NRM) are detailed. Prospective studies are needed to determine more precisely which lower risk MDS patients may benefit from transplantation.

Entities:  

Mesh：

Year:  2020        PMID： 32661295     DOI： 10.1038/s41375-020-0967-x

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


  43 in total

1.  Revised international prognostic scoring system for myelodysplastic syndromes.

Authors:  Peter L Greenberg; Heinz Tuechler; Julie Schanz; Guillermo Sanz; Guillermo Garcia-Manero; Francesc Solé; John M Bennett; David Bowen; Pierre Fenaux; Francois Dreyfus; Hagop Kantarjian; Andrea Kuendgen; Alessandro Levis; Luca Malcovati; Mario Cazzola; Jaroslav Cermak; Christa Fonatsch; Michelle M Le Beau; Marilyn L Slovak; Otto Krieger; Michael Luebbert; Jaroslaw Maciejewski; Silvia M M Magalhaes; Yasushi Miyazaki; Michael Pfeilstöcker; Mikkael Sekeres; Wolfgang R Sperr; Reinhard Stauder; Sudhir Tauro; Peter Valent; Teresa Vallespi; Arjan A van de Loosdrecht; Ulrich Germing; Detlef Haase
Journal:  Blood       Date:  2012-06-27       Impact factor: 22.113

2.  Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation.

Authors:  Amer M Zeidan; Maximilian Stahl; Xin Hu; Rong Wang; Scott F Huntington; Nikolai A Podoltsev; Steven D Gore; Xiaomei Ma; Amy J Davidoff
Journal:  Blood       Date:  2017-12-19       Impact factor: 22.113

3.  International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors:  P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

4.  Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.

Authors:  John Koreth; Joseph Pidala; Waleska S Perez; H Joachim Deeg; Guillermo Garcia-Manero; Luca Malcovati; Mario Cazzola; Sophie Park; Raphael Itzykson; Lionel Ades; Pierre Fenaux; Martin Jadersten; Eva Hellstrom-Lindberg; Robert Peter Gale; C L Beach; Stephanie J Lee; Mary M Horowitz; Peter L Greenberg; Martin S Tallman; John F DiPersio; Donald Bunjes; Daniel J Weisdorf; Corey Cutler
Journal:  J Clin Oncol       Date:  2013-06-24       Impact factor: 44.544

5.  Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System.

Authors:  M G Della Porta; C H Jackson; E P Alessandrino; M Rossi; A Bacigalupo; M T van Lint; M Bernardi; B Allione; A Bosi; S Guidi; V Santini; L Malcovati; M Ubezio; C Milanesi; E Todisco; M T Voso; P Musto; F Onida; A P Iori; R Cerretti; G Grillo; A Molteni; P Pioltelli; L Borin; E Angelucci; E Oldani; S Sica; C Pascutto; V Ferretti; A Santoro; F Bonifazi; M Cazzola; A Rambaldi
Journal:  Leukemia       Date:  2017-03-21       Impact factor: 11.528

6.  Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.

Authors:  A M Zeidan; N Al Ali; J Barnard; E Padron; J E Lancet; M A Sekeres; D P Steensma; A DeZern; G Roboz; E Jabbour; G Garcia-Manero; A List; R Komrokji
Journal:  Leukemia       Date:  2017-01-23       Impact factor: 11.528

7.  HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM.

Authors:  M Robin; R Porcher; L Adès; E Raffoux; M Michallet; S François; J-Y Cahn; A Delmer; E Wattel; S Vigouroux; J-O Bay; J Cornillon; A Huynh; S Nguyen; M-T Rubio; L Vincent; N Maillard; A Charbonnier; R P de Latour; O Reman; H Dombret; P Fenaux; G Socié
Journal:  Leukemia       Date:  2015-02-13       Impact factor: 11.528

8.  A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.

Authors:  Corey S Cutler; Stephanie J Lee; Peter Greenberg; H Joachim Deeg; Waleska S Pérez; Claudio Anasetti; Brian J Bolwell; Mitchell S Cairo; Robert Peter Gale; John P Klein; Hillard M Lazarus; Jane L Liesveld; Philip L McCarthy; Gustavo A Milone; J Douglas Rizzo; Kirk R Schultz; Michael E Trigg; Armand Keating; Daniel J Weisdorf; Joseph H Antin; Mary M Horowitz
Journal:  Blood       Date:  2004-03-23       Impact factor: 22.113

9.  Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia.

Authors:  Johannes Schetelig; Liesbeth C de Wreede; Michel van Gelder; Linda Koster; Jürgen Finke; Dietger Niederwieser; Dietrich Beelen; G J Mufti; Uwe Platzbecker; Arnold Ganser; Silke Heidenreich; Johan Maertens; Gerard Socié; Arne Brecht; Matthias Stelljes; Guido Kobbe; Liisa Volin; Arnon Nagler; Antonin Vitek; Thomas Luft; Per Ljungman; Ibrahim Yakoub-Agha; Marie Robin; Nicolaus Kröger
Journal:  Leukemia       Date:  2018-12-20       Impact factor: 11.528

10.  Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.

Authors:  Fernando Ramos; Cristina Robledo; Francisco Miguel Izquierdo-García; Dimas Suárez-Vilela; Rocío Benito; Marta Fuertes; Andrés Insunza; Eva Barragán; Mónica Del Rey; José María García-Ruiz de Morales; Mar Tormo; Eduardo Salido; Lurdes Zamora; Carmen Pedro; Javier Sánchez-Del-Real; María Díez-Campelo; Consuelo Del Cañizo; Guillermo F Sanz; Jesús María Hernández-Rivas
Journal:  Oncotarget       Date:  2016-05-24
View more
  4 in total

Review 1.  The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside.

Authors:  Yimei Feng; Xiaoli Chen; Kaniel Cassady; Zhongmin Zou; Shijie Yang; Zheng Wang; Xi Zhang
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

2.  [Guideline of the diagnosis and treatment of chronic myelomonocytic leukemia (2021)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-01-14

Review 3.  Past, present and future in low-risk myelodysplastic syndrome.

Authors:  Selami Kocak Toprak
Journal:  Front Med (Lausanne)       Date:  2022-07-15

4.  Failure to reach hematopoietic allogenic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study.

Authors:  C Lindholm; E Olofsson; M Creignou; L Nilsson; H Gravdahl Garelius; J Cammenga; P Ljungman; E Ejerblad; M Tobiasson
Journal:  Bone Marrow Transplant       Date:  2022-02-02       Impact factor: 5.483
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.